172 related articles for article (PubMed ID: 10363991)
1. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
Molldrem JJ; Lee PP; Wang C; Champlin RE; Davis MM
Cancer Res; 1999 Jun; 59(11):2675-81. PubMed ID: 10363991
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.
Molldrem JJ; Clave E; Jiang YZ; Mavroudis D; Raptis A; Hensel N; Agarwala V; Barrett AJ
Blood; 1997 Oct; 90(7):2529-34. PubMed ID: 9326217
[TBL] [Abstract][Full Text] [Related]
3. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
4. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.
St John LS; Wan L; He H; Garber HR; Clise-Dwyer K; Alatrash G; Rezvani K; Shpall EJ; Bollard CM; Ma Q; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):995-1001. PubMed ID: 27378343
[TBL] [Abstract][Full Text] [Related]
5. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.
Molldrem JJ; Lee PP; Wang C; Felio K; Kantarjian HM; Champlin RE; Davis MM
Nat Med; 2000 Sep; 6(9):1018-23. PubMed ID: 10973322
[TBL] [Abstract][Full Text] [Related]
6. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase.
Fujiwara H; El Ouriaghli F; Grube M; Price DA; Rezvani K; Gostick E; Sconocchia G; Melenhorst J; Hensel N; Douek DC; Barrett AJ
Blood; 2004 Apr; 103(8):3076-83. PubMed ID: 15070688
[TBL] [Abstract][Full Text] [Related]
7. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.
Molldrem J; Dermime S; Parker K; Jiang YZ; Mavroudis D; Hensel N; Fukushima P; Barrett AJ
Blood; 1996 Oct; 88(7):2450-7. PubMed ID: 8839835
[TBL] [Abstract][Full Text] [Related]
8. [Construction of HLA-A2-peptide tetramer and application in HBV/HCV infection].
Piao WH; He Y; Xi HL; Sun XT; Zhang HH; Xu JH; Zhao H; Xu WX; Li ZL; Wang GQ
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(21):1818-22. PubMed ID: 15631781
[TBL] [Abstract][Full Text] [Related]
9. HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma.
Jiang X; Lu X; Liu R; Zhang F; Zhao H
Clin Cancer Res; 2007 Dec; 13(24):7329-34. PubMed ID: 18094414
[TBL] [Abstract][Full Text] [Related]
10. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
11. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
[TBL] [Abstract][Full Text] [Related]
12. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739
[TBL] [Abstract][Full Text] [Related]
13. A constructed HLA-A2-restricted pMAGE-A1(278-286) tetramer detects specific cytotoxic T lymphocytes in tumour tissues in situ.
Mongkhoune S; Xie YA; Wang YQ; Chen Y; Zhou N; Peng Y; He J; Yu X; Zhou SF; Luo GR; Zhao YX; Lu XL
J Int Med Res; 2013 Dec; 41(6):1811-24. PubMed ID: 24071590
[TBL] [Abstract][Full Text] [Related]
14. Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein.
Weng X; Lu S; Zhong M; Liang Z; Shen G; Chen J; Wu X
J Leukoc Biol; 2009 Mar; 85(3):574-81. PubMed ID: 19112092
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
Molldrem JJ; Lee PP; Kant S; Wieder E; Jiang W; Lu S; Wang C; Davis MM
J Clin Invest; 2003 Mar; 111(5):639-47. PubMed ID: 12618518
[TBL] [Abstract][Full Text] [Related]
16. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
Bae J; Martinson JA; Klingemann HG
Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
[TBL] [Abstract][Full Text] [Related]
18. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.
Valmori D; Pittet MJ; Vonarbourg C; Rimoldi D; Liénard D; Speiser D; Dunbar R; Cerundolo V; Cerottini JC; Romero P
Cancer Res; 1999 Aug; 59(16):4050-5. PubMed ID: 10463606
[TBL] [Abstract][Full Text] [Related]
20. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
